GO:0004230 glutamyl aminopeptidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004230 glutamyl aminopeptidase activity describes the catalysis of the release of an N-terminal glutamate, and to a lesser extent aspartate, from a peptide.
• The term is synonymous with aminopeptidase A (APA), angiotensinase A, and several other names reflecting its broad substrate specificity and tissue distribution.
• Glutamyl aminopeptidase activity is involved in blood pressure regulation through the renin-angiotensin system, as it converts angiotensin II to angiotensin III.
• Altered glutamyl aminopeptidase activity has been reported in renal neoplasms, mammary tumours, and Alzheimer's disease, suggesting its potential as a biomarker or therapeutic target.
• The enzyme is also found in immune tissues, with activity changes observed in adenoid hyperplasia, tonsillar hyperplasia, and chronic tonsillitis.
• Studying this activity requires a combination of enzymatic assays, CRISPR-based gene editing, and expression profiling to link genotype to function.
Description
Glutamyl aminopeptidase activity (GO:0004230) is a molecular function defined as the catalysis of the release of an N-terminal glutamate, and to a lesser extent aspartate, from a peptide. This activity is attributed to the enzyme aminopeptidase A (APA), a membrane-bound zinc metallopeptidase that plays key roles in the renin-angiotensin system and in the processing of bioactive peptides. The term is also known by synonyms such as angiotensinase A, angiotensinase A2, and antigen BP-1/6C3 of mouse B lymphocytes, reflecting its historical identification in different contexts. Researchers study this activity because it is implicated in hypertension, cancer, and neurodegenerative disorders, and because it serves as a model for understanding peptide hormone processing. The enzyme's ability to cleave N-terminal acidic residues distinguishes it from other aminopeptidases and makes it a critical regulator of peptide half-life and receptor interaction. In this article, we explore the definition, mechanism, genes, and research methods associated with GO:0004230, providing a comprehensive resource for biomedical scientists.
glutamyl aminopeptidase activity At A Glance
| GO ID | GO:0004230 |
|---|---|
| GO term | glutamyl aminopeptidase activity |
| Ontology | molecular_function |
| Synonym | aminopeptidase A, angiotensinase A, angiotensinase A2, antigen BP-1/6C3 of mouse B lymphocytes, aspartate aminopeptidase activity, Ca2+-activated glutamate aminopeptidase activity, glutamyl peptidase activity, L-aspartate aminopeptidase activity, membrane aminopeptidase II |
| Major function | Catalysis of the release of an N-terminal glutamate (and to a lesser extent aspartate) from a peptide. |
| EC number | 3.4.11.7 (glutamyl aminopeptidase) |
| Cofactor | Zinc (Zn2+) is typically required for catalytic activity. |
| Subcellular location | Membrane-bound and soluble forms exist; often found on the cell surface. |
| Substrates | Peptides with N-terminal glutamate or aspartate, including angiotensin II. |
What Is GO:0004230?
Glutamyl aminopeptidase activity (GO:0004230) is the catalytic function of releasing an N-terminal glutamate, and to a lesser extent aspartate, from a peptide. This activity is mediated by enzymes such as aminopeptidase A, which are zinc-dependent metallopeptidases that cleave acidic amino acids from the amino terminus of polypeptide chains. The term encompasses several synonyms, including aminopeptidase A, angiotensinase A, and aspartate aminopeptidase activity, reflecting variations in substrate specificity and tissue sources. It is a molecular_function in the Gene Ontology, meaning it describes a specific biochemical activity rather than a biological process or cellular component.
Why Is glutamyl aminopeptidase activity Important in Cell Biology?
Glutamyl aminopeptidase activity is important because it regulates the bioavailability of peptide hormones and neurotransmitters, particularly within the renin-angiotensin system where it converts angiotensin II to angiotensin III, thereby influencing blood pressure and fluid balance. Dysregulation of this activity has been linked to hypertension, renal cell carcinoma, mammary tumours, and Alzheimer's disease, making it a potential therapeutic target and biomarker. Additionally, its presence in immune tissues suggests roles in immune regulation and inflammation. Understanding this activity at the molecular level can inform drug development and diagnostic strategies.
• Regulates blood pressure via the renin-angiotensin system by converting angiotensin II to angiotensin III.
• Altered activity is observed in renal neoplasms, indicating a potential role in cancer progression.
• Reduced plasma activity has been reported in sporadic Alzheimer's disease, suggesting a link to neurodegeneration.
• Activity changes are associated with N-methyl nitrosourea-induced rat mammary tumours.
• Involved in immune responses, with activity differences in adenoid hyperplasia, tonsillar hyperplasia, and chronic tonsillitis.
• Serves as a target for antihypertensive therapy development.
• Plays a role in peptide processing in various tissues, affecting hormone and cytokine signaling.
• Can be studied using CRISPR gene editing to dissect its function in specific cell types.
• Its bacterial homologs have industrial applications, such as in soy sauce fermentation.
• May interact with viral pathogens, as suggested by host-pathogen interaction studies.
Mechanism, Genes and Research Methods of glutamyl aminopeptidase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs onto the end of a peptide that starts with glutamate or aspartate.
Glutamyl aminopeptidase activity begins with the recognition of a peptide substrate bearing an N-terminal glutamate or aspartate residue. The enzyme's active site contains a zinc ion that coordinates the substrate's amino terminus and polarizes the peptide bond for cleavage. This specificity distinguishes it from other aminopeptidases that prefer neutral or basic residues. The binding is facilitated by electrostatic interactions between the negatively charged side chain of the N-terminal acidic residue and positively charged residues in the enzyme's substrate-binding pocket.
Catalytic Cleavage
In simple terms: The enzyme cuts off the first amino acid from the peptide chain.
Once bound, the enzyme catalyzes the hydrolysis of the peptide bond between the N-terminal glutamate (or aspartate) and the second amino acid. The zinc ion activates a water molecule that attacks the carbonyl carbon, leading to the release of the free acidic amino acid and a truncated peptide. This reaction is essential for the maturation or degradation of bioactive peptides such as angiotensin II, which is converted to angiotensin III. The catalytic efficiency can vary depending on pH, calcium ions, and the presence of inhibitors.
Post-Cleavage Product Release
In simple terms: After cutting, the enzyme lets go of the products so it can work on another peptide.
Following cleavage, the enzyme releases the N-terminal amino acid and the remaining peptide fragment. The truncated peptide may have altered biological activity, such as angiotensin III retaining some but not all functions of angiotensin II. The enzyme then undergoes conformational changes to reset its active site for another round of catalysis. This step is crucial for regulating the duration and intensity of peptide signaling.
Regulation by Cofactors and Inhibitors
In simple terms: The enzyme's activity can be turned up or down by other molecules.
Glutamyl aminopeptidase activity is dependent on zinc ions for catalysis and can be modulated by calcium ions, which may enhance or stabilize the enzyme. Specific inhibitors, such as amastatin and bestatin, can block its activity, while angiotensin II itself can act as a competitive substrate. In pathophysiological conditions, the expression and activity of the enzyme can be altered, as seen in renal neoplasms and Alzheimer's disease. These regulatory mechanisms provide targets for pharmacological intervention.
Key Genes Involved in GO:0004230 glutamyl aminopeptidase activity
The following genes and proteins are directly associated with glutamyl aminopeptidase activity, either as the enzyme itself or as key regulators and substrates.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ENPEP | Encodes aminopeptidase A, the primary enzyme with glutamyl aminopeptidase activity | Target for hypertension and cancer studies; expression altered in renal neoplasms |
| REN | Encodes renin, which initiates the renin-angiotensin system | Upstream regulator of angiotensin peptides that are substrates for APA |
| ACE | Encodes angiotensin-converting enzyme, which produces angiotensin II | Provides substrate for APA; interplay affects blood pressure |
| AGTR1 | Encodes angiotensin II receptor type 1 | Mediates effects of angiotensin II and III; APA modulates ligand availability |
| AGTR2 | Encodes angiotensin II receptor type 2 | May mediate effects of angiotensin III produced by APA |
| ANPEP | Encodes aminopeptidase N, another aminopeptidase | Can compensate or interact in peptide processing; used as comparison in studies |
| DPP4 | Encodes dipeptidyl peptidase IV, a related peptidase | Studied alongside APA in immune tissues |
| LNPEP | Encodes leucyl/cystinyl aminopeptidase | Another aminopeptidase with overlapping functions; potential redundancy |
| Bacillus amyloliquefaciens phb03 glutamyl aminopeptidase | Bacterial enzyme with novel degradation activity | Industrial applications in soy sauce fermentation and salt tolerance |
| HCoV-229E | Human coronavirus that may interact with aminopeptidases | Host-pathogen interaction studies suggest potential role |
| BP-1/6C3 antigen | Mouse B lymphocyte antigen identical to aminopeptidase A | Immune function research; marker for B cell studies |
| Calcium ions | Cofactor that can activate glutamyl aminopeptidase | Modulates enzyme activity in vitro and in vivo |
| Zinc ions | Essential cofactor for catalytic activity | Required for metallopeptidase function |
| Amastatin | Inhibitor of aminopeptidase A | Used experimentally to block activity |
| Bestatin | Inhibitor of aminopeptidases | Research tool for studying enzyme contribution |
| Angiotensin II | Substrate for glutamyl aminopeptidase | Central to blood pressure regulation |
| Angiotensin III | Product of glutamyl aminopeptidase activity | Biologically active peptide with roles in aldosterone release |
How Is glutamyl aminopeptidase activity Regulated?
Glutamyl aminopeptidase activity is regulated at multiple levels. Transcriptionally, the ENPEP gene can be modulated by factors influencing renal and vascular function. Post-translationally, the enzyme requires zinc for activity and can be activated by calcium ions. Competitive inhibitors such as angiotensin II and pharmacological inhibitors like amastatin can reduce activity. In disease states, altered expression and activity have been observed, suggesting dysregulation in cancer and neurodegeneration.
glutamyl aminopeptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ENPEP | Hypertension | Knockout mouse models to assess blood pressure regulation |
| ENPEP | Renal neoplasms | Renal cell carcinoma cell lines with ENPEP overexpression or knockout |
| ENPEP | Alzheimer's disease | Neuronal cell models to study peptide processing |
| ENPEP | Mammary tumours | Rat mammary tumour models or human breast cancer cell lines |
| ENPEP | Immune disorders | B cell lines and tonsillar tissue samples |
Hypertension and Cardiovascular Disease
Glutamyl aminopeptidase activity is integral to the renin-angiotensin system, where it converts angiotensin II to angiotensin III. This conversion affects blood pressure regulation, and inhibition of APA has been proposed as a therapeutic strategy for hypertension. Studies suggest that modulating this activity can influence vascular tone and fluid balance, making it a target for antihypertensive drug development.
Renal Neoplasms
Altered glutamyl aminopeptidase activity and expression have been reported in renal neoplasms. Blanco et al. (2014) found changes in activity and expression in renal cell carcinoma, suggesting a potential role in tumorigenesis or as a diagnostic marker. The enzyme's involvement in peptide processing may affect tumor growth and angiogenesis.
Alzheimer's Disease
Reduced plasma glutamyl aminopeptidase activity has been observed in sporadic Alzheimer's disease. Kuda et al. (1997) reported a significant reduction in activity, which may reflect systemic changes in peptide metabolism associated with neurodegeneration. This finding suggests a possible biomarker or pathophysiological link.
Mammary Tumours
In N-methyl nitrosourea-induced rat mammary tumours, glutamyl aminopeptidase activity was modified, while aspartyl aminopeptidase activity was not. Carrera et al. (2004) suggested that this specific change may be relevant to breast cancer biology and could be explored as a therapeutic target.
From glutamyl aminopeptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of ENPEP knockout on angiotensin II processing? | ENPEP knockout mice or CRISPR-Cas9 knockout in cell lines |
| How does a point mutation in the catalytic site affect enzyme activity? | Point-mutation knock-in cell lines expressing mutant ENPEP |
| Can we tag ENPEP to track its localization? | Knock-in of fluorescent or epitope tags at the endogenous locus |
| What happens when ENPEP is overexpressed in cancer cells? | Overexpression cell models using lentiviral vectors |
| Which genes interact with ENPEP in hypertension? | CRISPR library screening in vascular smooth muscle cells |
| How does ENPEP activity change in Alzheimer's disease? | Patient-derived induced pluripotent stem cells differentiated into neurons |
How to Study the glutamyl aminopeptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorogenic activity assay | Enzymatic cleavage of glutamyl substrate | Quantifying activity in cell lysates or serum |
| qRT-PCR | ENPEP mRNA levels | Expression profiling in disease tissues |
| Western blot | ENPEP protein levels | Validating expression changes |
| Immunohistochemistry | Tissue localization of ENPEP | Studying distribution in tumors |
| CRISPR-Cas9 knockout | Loss of ENPEP function | Determining causal roles in cells |
| Mass spectrometry | Peptide substrates and products | Identifying novel peptide targets |
| Inhibitor profiling | Sensitivity to amastatin/bestatin | Characterizing enzyme specificity |
Enzymatic Activity Assays
Glutamyl aminopeptidase activity is typically measured using fluorogenic or chromogenic substrates such as glutamyl-7-amido-4-methylcoumarin. These assays quantify the release of the N-terminal amino acid and can be performed on cell lysates, serum, or purified enzyme preparations. They are essential for determining kinetic parameters and inhibitor efficacy.
Expression Analysis
Quantitative PCR, Western blotting, and immunohistochemistry are used to assess ENPEP mRNA and protein levels in tissues and cell lines. These methods help correlate activity with expression changes in disease states such as renal neoplasms and Alzheimer's disease.
CRISPR-Cas9 Gene Editing
CRISPR-Cas9 is employed to generate knockout, point-mutation, and knock-in models to study the causal role of ENPEP in cellular processes. These models allow researchers to dissect the specific contributions of glutamyl aminopeptidase activity to peptide processing and disease phenotypes.
Peptidomics and Mass Spectrometry
Mass spectrometry-based peptidomics can identify natural substrates and products of glutamyl aminopeptidase activity in biological samples. This approach provides unbiased insights into the enzyme's role in peptide metabolism and can reveal novel pathways.
How CRISPR Can Be Used to Study GO:0004230 glutamyl aminopeptidase activity
Knockout
CRISPR-Cas9 knockout of ENPEP eliminates glutamyl aminopeptidase activity, allowing researchers to study its role in angiotensin II processing, blood pressure regulation, and cancer cell proliferation. Knockout cell lines and animal models can reveal compensatory mechanisms and validate drug targets.
Point Mutation
Introducing point mutations in the catalytic domain of ENPEP can abrogate enzymatic activity while preserving protein structure, enabling the distinction between catalytic and non-catalytic functions. Such models are valuable for dissecting the specific contribution of glutamyl aminopeptidase activity to disease phenotypes.
Knock-in
Knock-in of epitope tags or fluorescent proteins at the endogenous ENPEP locus allows real-time tracking of enzyme localization and dynamics. This approach can also be used to introduce disease-associated mutations for functional studies.
Overexpression
Overexpression of ENPEP in cell lines can mimic pathological states where activity is elevated, such as in certain cancers. These models help identify downstream effects on peptide signaling and cell behavior, and can be used for drug screening.
How EDITGENE Supports glutamyl aminopeptidase activity Research
Researchers studying glutamyl aminopeptidase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genetic manipulation, which can be achieved through CRISPR-based gene editing services.
Contact EDITGENE today to design your custom CRISPR model for glutamyl aminopeptidase activity research.
Frequently Asked Questions About glutamyl aminopeptidase activity
What is glutamyl aminopeptidase activity?
Glutamyl aminopeptidase activity (GO:0004230) is the catalysis of the release of an N-terminal glutamate, and to a lesser extent aspartate, from a peptide. It is mediated by enzymes such as aminopeptidase A.
What genes are involved in glutamyl aminopeptidase activity?
The primary gene is ENPEP, which encodes aminopeptidase A. Other related genes include REN, ACE, and AGTR1, which are part of the renin-angiotensin system.
What diseases are associated with glutamyl aminopeptidase activity?
It has been linked to hypertension, renal neoplasms, Alzheimer's disease, mammary tumours, and immune disorders.
How is glutamyl aminopeptidase activity measured?
It is commonly measured using fluorogenic substrates such as glutamyl-7-amido-4-methylcoumarin in activity assays.
What are the synonyms for glutamyl aminopeptidase activity?
Synonyms include aminopeptidase A, angiotensinase A, angiotensinase A2, aspartate aminopeptidase activity, and membrane aminopeptidase II.
What is the role of glutamyl aminopeptidase in blood pressure?
It converts angiotensin II to angiotensin III, thereby modulating blood pressure and fluid balance.
Can glutamyl aminopeptidase activity be inhibited?
Yes, inhibitors such as amastatin and bestatin can block its activity, and this is used in research and potential therapy.
Is glutamyl aminopeptidase activity found in bacteria?
Yes, a bacterial glutamyl aminopeptidase from Bacillus amyloliquefaciens has been characterized with novel degradation activity.
How can CRISPR be used to study glutamyl aminopeptidase activity?
CRISPR-Cas9 can generate knockout, point-mutation, and knock-in models to dissect the function of ENPEP and its role in disease.
What are the research methods for studying glutamyl aminopeptidase activity?
Methods include enzymatic assays, qRT-PCR, Western blot, immunohistochemistry, CRISPR editing, and mass spectrometry.
Conclusion
Glutamyl aminopeptidase activity (GO:0004230) is a critical molecular function involved in peptide processing, with significant implications for hypertension, cancer, and neurodegeneration. Understanding its mechanism and regulation provides opportunities for therapeutic intervention. Researchers can leverage CRISPR-based models and a suite of biochemical assays to explore its roles in health and disease.
References
- 1. Zeng LY et al.. 2025. Characterization of Glutamyl Aminopeptidase with Novel Degradation Activity of Soybean Trypsin Inhibitor and Salt-Tolerance from Bacillus amyloliquefaciens phb03 in Soy Sauce Residue.. J Agric Food Chem 73(22):13663-13675 PMID: 40420398
- 2. Fung TS et al.. 2019. Human Coronavirus: Host-Pathogen Interaction.. Annu Rev Microbiol 73:529-557 PMID: 31226023
- 3. Blanco L et al.. 2014. Altered glutamyl-aminopeptidase activity and expression in renal neoplasms.. BMC Cancer 14:386 PMID: 24885240
- 4. Stewart MH et al.. 2018. Future pharmacological therapy in hypertension.. Curr Opin Cardiol 33(4):408-415 PMID: 29702500
- 5. Kuda T et al.. 1997. Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease.. Biochem Biophys Res Commun 231(3):526-30 PMID: 9070837
- 6. Carrera MP et al.. 2004. Glutamyl- but not aspartyl-aminopeptidase activity is modified in serum of N-methyl nitrosourea-induced rat mammary tumours.. Anticancer Res 24(2B):801-5 PMID: 15161030
- 7. Larrinaga G et al.. 2011. Activity of soluble aminopeptidase A and dipeptidyl peptidase IV and membrane-bound aminopeptidase B and pyroglutamyl peptidase I in adenoid hyperplasia, tonsillar hyperplasia and chronic tonsillitis.. Int J Pediatr Otorhinolaryngol 75(11):1399-403 PMID: 21937126
- 8. Sharma P et al.. 2024. Aminopeptidase A: A Novel Therapeutic Target for Hypertension Management.. Cell Biochem Funct 42(8):e70008 PMID: 39445480
